
pmid: 17543138
handle: 11573/231072 , 11568/195596 , 2318/1613164
The present review provides an update of the available data and discusses research issues relating to ultrasound (US) imaging in osteoarthritis (OA). Currently, the principal indications for using US in OA include: delineation of changes within articular cartilage (AC) and demonstration of synovial and adjacent soft tissue pathology together with injection into OA joints under US guidance. US has been proposed as a possible imaging tool for following the progression of OA. The main priorities requiring the attention of researchers include: addressing difficulties surrounding consensus on definitions of pathology in OA, charting the natural history of AC change in site specific OA, investigation of the link between inflammation and OA and the use of three-dimensional (3D) US in OA.
Cartilage, Articular, Inflammation, Osteoarthritis, Synovial Membrane, Disease Progression, Humans, osteophyte; articular cartilage; ultrasonography; synovitis; osteoarthritis, Ultrasonography
Cartilage, Articular, Inflammation, Osteoarthritis, Synovial Membrane, Disease Progression, Humans, osteophyte; articular cartilage; ultrasonography; synovitis; osteoarthritis, Ultrasonography
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 55 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
